BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Nestin is a protein belonging to class VI of intermediate filaments that is produced in stem/progenitor cells in the mammalian CNS during development and is consecutively replaced by other intermediate filament proteins (neurofilaments, GFAP).

Down-regulated nestin may be re-expressed in the adult organism under certain pathological conditions (brain injury, ischemia, inflammation, neoplastic transformation).

Our work focused on a detailed study of the nestin cytoskeleton in cell lines derived from glioblastoma multiforme, because re-expression of nestin together with down-regulation of GFAP has been previously reported in this type of brain tumor.

METHODS: Two cell lines were derived from the tumor tissue of patients treated for glioblastoma multiforme.

CONCLUSION: Detailed information concerning the pattern of the nestin cytoskeleton in glioblastoma cell lines and especially the demonstration of nestin in the nucleus represent an important background for further studies of nestin re-expression in relationship to tumor malignancy and invasive potential.

[MeSH-minor] Cell Line, Tumor. Cytoskeleton / chemistry. Cytoskeleton / ultrastructure. Fluorescent Antibody Technique, Indirect. Glial Fibrillary Acidic Protein / analysis. Humans. Nestin. Vimentin / analysis

Genetic Alliance. consumer health - Glioblastoma.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):503-15 [10571412.001]

[Cites] Exp Cell Res. 2003 Apr 1;284(2):185-95 [12651152.001]

[Cites] Exp Cell Res. 2000 Feb 1;254(2):269-78 [10640425.001]

[Cites] Mol Biol Cell. 2003 Apr;14(4):1468-78 [12686602.001]

[Cites] Mol Cell Biol. 2003 Jul;23(14):5090-106 [12832492.001]

[Cites] Neoplasia. 2003 Nov-Dec;5(6):520-32 [14965445.001]

[Cites] Exp Mol Med. 2004 Feb 29;36(1):52-6 [15031671.001]

[Cites] J Biol Chem. 2004 Jul 2;279(27):27994-9 [15117961.001]

[Cites] J Neurosci. 1985 Dec;5(12):3310-28 [4078630.001]

[Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]

[Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]

[Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]

[Cites] J Cell Sci. 1992 Oct;103 ( Pt 2):589-97 [1478958.001]

[Cites] Cancer Res. 1994 Jan 15;54(2):354-6 [8275467.001]

[Cites] Exp Cell Res. 1994 Oct;214(2):447-58 [7925640.001]

[Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]

[Cites] Brain Res Dev Brain Res. 1995 Jan 14;84(1):109-29 [7720210.001]

[Cites] Lab Invest. 1996 Jan;74(1):188-98 [8569181.001]

[Cites] Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):913-25 [9353831.001]

[Cites] J Struct Biol. 1997 Oct;120(1):61-8 [9356292.001]

[Cites] Pediatr Res. 1998 Mar;43(3):386-92 [9505279.001]

[Cites] Exp Cell Res. 1998 Mar 15;239(2):332-43 [9521851.001]

[Cites] Am J Pathol. 1998 Oct;153(4):1157-68 [9777947.001]

[Cites] J Biol Chem. 1999 Aug 20;274(34):23996-4006 [10446168.001]

[Cites] Histol Histopathol. 2005 Apr;20(2):665-71 [15736068.001]

[Cites] J Cell Sci. 1998 Dec 18;111 ( Pt 24):3573-84 [9819349.001]

[Cites] Curr Opin Cell Biol. 2000 Feb;12(1):79-90 [10679360.001]

[Cites] Exp Neurol. 2000 Feb;161(2):585-96 [10686078.001]

[Cites] Int J Dev Neurosci. 2001 Feb;19(1):101-8 [11226759.001]

[Cites] Am J Pathol. 2001 Mar;158(3):817-23 [11238030.001]

[Cites] J Biol Chem. 2001 May 11;276(19):16456-63 [11278541.001]

[Cites] J Neurosci. 2001 Aug 15;21(16):6147-58 [11487638.001]

[Cites] Stem Cells. 2001;19(5):419-24 [11553850.001]

[Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]

[Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]

[Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]

[Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]

[Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]

[Cites] Cancer. 2002 Aug 1;95(3):641-55 [12209758.001]

[Cites] Int J Oncol. 2002 Oct;21(4):775-85 [12239616.001]

[Cites] Neurosci Res. 2002 Oct;44(2):207-12 [12354635.001]

[Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]

(PMID = 16457706.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Vimentin

[Other-IDs] NLM/ PMC1403792

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome.

PURPOSE: The prognostic significance of human chorionic gonadotropin (HCG) level in central nervous system germinoma remains controversial.

METHODS AND MATERIALS: We undertook a multi-institutional retrospective analysis of 103 patients with central nervous system germinoma whose serum HCG and/or beta-HCG level had been measured before treatment between 1984 and 2002.

The proportion of HCG-producing tumors was higher in the lesions at the basal ganglia than in the lesions at the other sites.

No correlation was found between tumor size and HCG level, but there seemed to be a weak correlation between size and beta-HCG.

Also, no other patient-, tumor-, or treatment-related factors seemed to influence the prognosis of the patients.

Relationship between tumor size and site and HCG level should be investigated further.

[MeSH-major] Central Nervous System Neoplasms / blood. Chorionic Gonadotropin / blood. Germinoma / blood. Neoplasm Proteins / blood

[MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Germinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15936563.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Neoplasm Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Psychiatric symptoms associated with brain tumors: a clinical enigma.

Patients in psychiatric settings may present with medical conditions, such as brain tumors, which may or may not be associated with neurological symptoms.

Brain tumors may be detected in patients at their first presentation to mental health services or sometimes in patients with well-established psychiatric diagnoses.

Brain imaging showed the presence of a left thalamic tumor, later confirmed as glioblastoma multiforme.

With this we show that in some cases, brain tumors can be neurologically silent and only present atypical psychiatric symptoms.

[MeSH-major] Brain Neoplasms / complications. Depressive Disorder, Major / etiology. Stress Disorders, Post-Traumatic / etiology

[MeSH-minor] Adult. Female. Functional Laterality. Humans. Severity of Illness Index. Thalamus / surgery

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16400253.001).

[ISSN] 1092-8529

[Journal-full-title] CNS spectrums

[ISO-abbreviation] CNS Spectr

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.

OBJECTIVE: The current study was conducted to evaluate the effects of low-dose craniospinal irradiation (CSI) combined with chemotherapy on non-metastatic embryonal tumors in the central nervous system (CNS), including medulloblastoma and supra-tentorial primitive neuroectodermal tumors (ST-PNET).

The dose to the primary tumor bed was 39.6-54 Gy.

CONCLUSION: Low-dose CSI and ICE chemotherapy may have a role as a treatment option for a subset of patients with non-metastatic embryonal tumors in the CNS.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Cranial Irradiation. Medulloblastoma / therapy. Neuroectodermal Tumors, Primitive / therapy

[MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Male. Radiotherapy Dosage. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / therapy. Survival Analysis

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. IFOSFAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18573848.001).

[ISSN] 1465-3621

[Journal-full-title] Japanese journal of clinical oncology

[ISO-abbreviation] Jpn. J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Japan

[Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.

PURPOSE: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL).

Univariate and multivariate analyses were conducted for age (</= 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no).

[MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Cohort Studies. Female. Health Status. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15800313.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.

PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.

Tumor samples were evaluated for AGT levels.

Future trials are required to determine if the inhibition of tumor AGT levels results in increased efficacy.

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. Carmustine .

Hazardous Substances Data Bank. GUANINE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]

[Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]

[Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]

[Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]

[Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]

[Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]

[Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]

[Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]

[Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]

[Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]

[Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]

[Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]

[Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]

[Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]

[Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]

[Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]

[Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]

[Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]

[Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]

[Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]

[Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]

[Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]

(PMID = 17264335.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015

[Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine

[Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Meningeal melanocytoma is a rare benign CNS tumor derived from the leptomeningeal melanocytes.

[MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Neoplasm Seeding. Spinal Cord Neoplasms / pathology

[MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19361258.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.

BACKGROUND: Adult survivors of childhood central nervous system (CNS) malignancies are at high risk for long-term morbidity and late mortality.

However, patterns of late mortality, the long-term risks of subsequent neoplasms and debilitating medical conditions, and sociodemographic outcomes have not been comprehensively characterized for individual diagnostic and treatment groups.

METHODS: We collected information on treatment, mortality, chronic medical conditions, and neurocognitive functioning of adult 5-year survivors of CNS malignancies diagnosed between 1970 and 1986 within the Childhood Cancer Survivor Study.

Using competing risk framework, we calculated cumulative mortality according to cause of death and cumulative incidence of subsequent neoplasms according to exposure and dose of cranial radiation therapy (RT).

Neurocognitive impairment and socioeconomic outcomes were assessed with respect to dose of CNS radiotherapy to specific brain regions.

Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent neoplasm within the CNS of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT.

Neurocognitive impairment was high and proportional to radiation dose for specific tumor types.

CONCLUSIONS: Survivors of childhood CNS malignancies are at high risk for late mortality and for developing subsequent neoplasms and chronic medical conditions.

Genetic Alliance. consumer health - Childhood Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]

[Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79 [18812549.001]

[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]

[Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]

[Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]

[Cites] J Neurol. 2002 Aug;249(8):955-60 [12195437.001]

[Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]

[Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]

[Cites] J Neurooncol. 2003 Jul;63(3):279-87 [12892234.001]

[Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]

[Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]

[Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]

[Cites] Pediatr Hematol Oncol. 2003 Dec;20(8):617-25 [14578032.001]

[Cites] Neuropsychology. 2003 Oct;17(4):548-55 [14599268.001]

[Cites] Curr Opin Neurol. 2003 Dec;16(6):677-83 [14624076.001]

[Cites] J Clin Oncol. 2004 Mar 15;22(6):999-1006 [15020603.001]

[Cites] Ann Fam Med. 2004 Jan-Feb;2(1):61-70 [15053285.001]

[Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]

[Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]

[Cites] Am J Epidemiol. 1986 Jan;123(1):174-84 [3509965.001]

[Cites] Am J Clin Oncol. 1985 Dec;8(6):472-6 [3936349.001]

[Cites] Arch Dis Child. 1990 Dec;65(12):1356-63 [2270944.001]

[Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]

[Cites] J Clin Oncol. 1992 Sep;10(9):1397-406 [1517782.001]

[Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]

[Cites] Int J Epidemiol. 1998 Feb;27(1):91-5 [9563700.001]

[Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]

[Cites] Ann Neurol. 1998 Sep;44(3):313-6 [9749596.001]

[Cites] Med Pediatr Oncol. 1998 Dec;31(6):506-11 [9835903.001]

[Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]

[Cites] J Neurooncol. 1999 Jan;41(1):47-53 [10222422.001]

[Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]

[Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]

[Cites] Pediatr Blood Cancer. 2005 Aug;45(2):155-61 [15880357.001]

[Cites] Pediatr Blood Cancer. 2006 May 1;46(5):637-44 [16421901.001]

[Cites] Pediatr Blood Cancer. 2006 Jul;47(1):83-8 [16317732.001]

[Cites] J Clin Oncol. 2006 Jun 1;24(16):2536-43 [16735706.001]

[Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]

[Cites] Haematologica. 2006 Aug;91(8):1084-91 [16870549.001]

[Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]

[Cites] Eur J Cancer. 2007 Jan;43(2):351-62 [17141498.001]

[Cites] Pediatr Blood Cancer. 2007 Apr;48(4):460-7 [16767717.001]

[Cites] J Clin Oncol. 2007 Apr 20;25(12):1532-8 [17442996.001]

[Cites] Pediatr Blood Cancer. 2007 Jul;49(1):47-51 [16755550.001]

[Cites] Blood. 2008 Apr 15;111(8):4014-21 [18258798.001]

[Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]

[Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]

[Cites] J Clin Oncol. 2008 Sep 20;26(27):4401-9 [18802152.001]

[CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):908-10 [19549957.001]

[CommentIn] J Natl Cancer Inst. 2009 Jul 1;101(13):909 [19549959.001]

(PMID = 19535780.001).

[ISSN] 1460-2105

[Journal-full-title] Journal of the National Cancer Institute

[ISO-abbreviation] J. Natl. Cancer Inst.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / U24-CA55727

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Other-IDs] NLM/ PMC2704230

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: The IF protein nestin and the RNA-binding protein musashi are expressed by neural progenitor cells during CNS development.

Their expression in glial tumors was evaluated by immunohistochemistry, and the histopathological scores correlated with levels of cysteine cathepsins that are known prognostic markers in several tumors.

METHODS: The levels of nestin, musashi, and cathepsins B and L were assessed by immunohistochemical analysis of biopsies from 87 patients with primary CNS tumors.

To confirm the immunohistochemical data, nestin expression was analyzed by real-time PCR in 12 brain tumor biopsies.

The total IHC score for nestin was significantly higher in high- than in low-grade tumors (P < .0001).

IHC staining of nestin in a xenograft model showed that its expression is localized mainly in the invasive tumor cells at the tumor periphery.

The presented data links the invasive glioma cells to CNS precursor cells, indicating that the most malignant cells in the gliomas may well be closely related to the glioma stem cells.

[MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism

[MeSH-minor] Adolescent. Adult. Aged. Animals. Cathepsin B / metabolism. Cathepsin L. Cathepsins / metabolism. Child. Child, Preschool. Cysteine Endopeptidases / metabolism. Female. Humans. Male. Middle Aged. Nestin. RNA, Messenger / metabolism. RNA-Binding Proteins / metabolism. Rats. Survival Rate

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17537489.001).

[ISSN] 0090-3019

[Journal-full-title] Surgical neurology

[ISO-abbreviation] Surg Neurol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / MSI1 protein, human; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L; EC 3.4.22.15 / Ctsl protein, rat

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In the past few years, the plasticity of the regional specification of the CNS has been widely debated on the results from in utero transplantation.

These lines were established from a cerebellum of an adult p53-deficient mouse.

Our results showed that transplanted cells migrated into various regions of the CNS and supported the independent distribution.

[MeSH-minor] Animals. Animals, Newborn. Biomarkers / metabolism. Blood Vessels / embryology. Cell Line. Cell Lineage / physiology. Cell Shape / physiology. Cell Survival / physiology. Clone Cells / cytology. Clone Cells / metabolism. Clone Cells / transplantation. Female. Male. Mice. Mice, Knockout. Nerve Tissue Proteins / metabolism. Neurites / ultrastructure. Organ Culture Techniques. Sex Characteristics. Time Factors. Tumor Suppressor Protein p53 / genetics

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17651850.001).

[ISSN] 0168-0102

[Journal-full-title] Neuroscience research

[ISO-abbreviation] Neurosci. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / Biomarkers; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Protein p53

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.

PURPOSE: The quality of life (QOL) and neurocognitive function of patients with brain tumors are negatively affected by the symptoms of their disease and brain radiation therapy (RT).

We assessed the effect of prophylactic d-threo-methylphenidate HCl (d-MPH), a central nervous system (CNS) stimulant on QOL and cognitive function in patients undergoing RT.

METHODS AND MATERIALS: Sixty-eight patients with primary or metastatic brain tumors were randomly assigned to receive d-MPH or placebo.

CONCLUSIONS: Prophylactic use of d-MPH in brain tumor patients undergoing RT did not result in an improvement in QOL.

[MeSH-major] Brain Neoplasms / radiotherapy. Central Nervous System Stimulants / therapeutic use. Cognition / drug effects. Fatigue / prevention & control. Methylphenidate / therapeutic use. Quality of Life

[MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Double-Blind Method. Female. Humans. Least-Squares Analysis. Male. Middle Aged. Patient Dropouts / statistics & numerical data. Prospective Studies

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Fatigue.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. METHYLPHENIDATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17869448.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 1 U10CA81851

[Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Studies of different national populations were indispensable for estimating the impact of illness-related disability on social outcomes in adult childhood cancer survivors.

RESULTS: Non-central nervous system (CNS) cancer survivors had similar education, employment, and income as the general population in adjusted models, whereas survivors of CNS tumors more often had no more than basic (< or =9 years) education (relative risk [RR], 1.80 [95% confidence interval (95% CI), 1.45-2.23]), less often attained education beyond secondary school (RR, 0.69 [95% CI, 0.58-0.81]), and less often were employed (RR, 0.85 [95% CI, 0.77-0.94]).

Predicted net income from work was lower in CNS tumor survivors (P <.001) than in the general population, even after the exclusion of individuals who received economic disability compensation.

CONCLUSIONS: CNS tumor survivors had poorer social outcomes compared with the general population, whereas outcomes for survivors of other childhood cancers were similar to the general population.

Established late effects highlighted the importance of improved, safer pediatric CNS tumor treatment protocols and surveillance that identified individual needs for preventive and remedial measures.

[MeSH-major] Neoplasms / therapy. Social Class. Survivors / statistics & numerical data

[MeSH-minor] Adult. Central Nervous System Neoplasms / economics. Child. Educational Status. Employment. Female. Follow-Up Studies. Humans. Income. Male. Population Surveillance. Sweden

Genetic Alliance. consumer health - Childhood Cancer.

MedlinePlus Health Information. consumer health - Cancer in Children.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20087961.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The objective of this study was to collect analysis of data and discuss certain epidemiologic features of neoplasm using data from hospital.

The tumors were coded and classified according to the International Classification of Diseases 10th revision and ICD-O.

The ten most frequent cancer sites among patients were breast (13.6%), brain &CNS (13.6%), skin(13.5%), haemapoitic system(9.7%), lymphoid (7.1%), esophagus (7.1%), colon & rectum (4%), male genital organs (1.3%), bladder (1.3%), lung (1.2%), and stomach (1%).

All tumors except the breast, female genital organs, thyroid, gallbladder and kidney cancers, were more frequent in males compared to women.

About 16.6% of tumors occurred in children aged 15 years or younger.

More than four fifths (81%) of patients with cancer of haematopoeitic system were under age of 15 years.

In conclusion, the results of this study present an important epidemiological understanding of patients with tumors.

It emphasizes that gender plays an important role in the frequency of primary tumors, and how much the sex ratio varies with some types of tumors.

We also noted that certain tumor types show a prediction for certain decades of life in our series.

[MeSH-major] Neoplasms / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Hospitals / statistics & numerical data. Humans. Incidence. Infant. Infant, Newborn. Iran / epidemiology. Male. Middle Aged. Risk Factors. Time Factors. Young Adult

MedlinePlus Health Information. consumer health - Cancer in Children.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18439094.001).

[ISSN] 2476-762X

[Journal-full-title] Asian Pacific journal of cancer prevention : APJCP

[ISO-abbreviation] Asian Pac. J. Cancer Prev.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Thailand

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.

PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking.

Several genetic changes including BCL6 rearrangements and deletion of 6q22, containing the putative tumor suppressor gene PTPRK, are potential risk predictors.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):776-82 [16896311.001]

[Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]

[Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):447-51 [12640061.001]

[Cites] Am J Surg Pathol. 2003 Apr;27(4):487-93 [12657933.001]

[Cites] Virchows Arch. 2003 Aug;443(2):164-9 [12802586.001]

[Cites] Cerebrovasc Dis. 2004;17(2-3):224-7 [14707426.001]

[Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]

[Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]

[Cites] Blood. 1994 Apr 1;83(7):1757-9 [8142643.001]

[Cites] Blood. 1994 May 1;83(9):2423-7 [8167331.001]

[Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]

[Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]

[Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]

[Cites] Blood. 1995 May 15;85(10):2877-84 [7742550.001]

[Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]

[Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]

[Cites] J Clin Oncol. 2005 Mar 1;23(7):1507-13 [15735126.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2233-9 [15800313.001]

[Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]

[Cites] J Clin Oncol. 2005 Aug 20;23(24):5718-27 [16009945.001]

[Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]

[Cites] Cancer. 2005 Dec 1;104(11):2466-72 [16240449.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]

[Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]

[Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]

[Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]

[Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]

[Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]

[Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]

[Cites] Nat Rev Immunol. 2005 Jan;5(1):43-57 [15630428.001]

[Cites] Am J Pathol. 1999 Nov;155(5):1445-51 [10550299.001]

[Cites] Am J Surg Pathol. 1999 Nov;23(11):1386-92 [10555007.001]

[Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]

[Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]

[Cites] Neurosurgery. 2000 Aug;47(2):454-6; discussion 456-7 [10942021.001]

[Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]

[Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):147-50 [11369058.001]

[Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]

[Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]

[Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33 [12387458.001]

[Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]

[Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]

[Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]

(PMID = 18645192.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA108961

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins

[Other-IDs] NLM/ PMC2653136

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Utilization of sperm banking was significantly associated with a diagnosis of central nervous system (CNS) malignancy or non-CNS solid tumor diagnosis, higher socioeconomic status, and not being a member of an Evangelical religious group.

Genetic Alliance. consumer health - infertility.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Male Infertility.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell Endocrinol. 2000 Nov 27;169(1-2):117-22 [11155943.001]

[Cites] Pediatr Blood Cancer. 2008 Jan;50(1):85-9 [17514741.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1880-9 [11919248.001]

[Cites] J Clin Oncol. 2002 Apr 1;20(7):1890-7 [11919249.001]

[Cites] Arch Dis Child. 2004 Aug;89(8):736-7 [15269072.001]

[Cites] Hum Reprod Update. 2004 Nov-Dec;10(6):525-32 [15319377.001]

[Cites] Cancer. 1992 Dec 1;70(11):2703-12 [1423201.001]

[Cites] Cancer. 1999 Aug 15;86(4):697-709 [10440699.001]

[Cites] Psychooncology. 2004 Oct;13(10):689-99 [15386645.001]

[Cites] Psychooncology. 2004 Dec;13(12):867-81 [15386796.001]

[Cites] J Natl Cancer Inst Monogr. 2005;(34):101-3 [15784836.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2917-31 [16651642.001]

[Cites] J Pediatr Hematol Oncol. 2006 Jun;28(6):350-4 [16794502.001]

[Cites] Hum Reprod. 2007 May;22(5):1384-95 [17259225.001]

[Cites] Cancer. 2007 Sep 1;110(5):1125-9 [17647219.001]

[Cites] Cancer. 2001 Feb 1;91(3):613-21 [11169946.001]

(PMID = 19437327.001).

[ISSN] 1521-0669

[Journal-full-title] Pediatric hematology and oncology

[ISO-abbreviation] Pediatr Hematol Oncol

[Language] ENG

[Grant] None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-31

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

[Other-IDs] NLM/ NIHMS162120; NLM/ PMC2801903

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Glioblastoma (GBM) is a malignant CNS neoplasm.

Stratified by age, resectability and tumor size <5 cm were favorable survival factors in young (40<yrs) and old age groups (> or =40 yrs), respectively.

Furthermore, the patients with supratentorial tumor lived longer than the patients with infratentorial tumor (p<0.05).

[MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism

[MeSH-minor] Adult. Age Factors. Brain / metabolism. Brain / surgery. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infratentorial Neoplasms / diagnosis. Infratentorial Neoplasms / metabolism. Infratentorial Neoplasms / mortality. Infratentorial Neoplasms / pathology. Male. PTEN Phosphohydrolase / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Prognosis. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Epidermal Growth Factor / metabolism. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / pathology. Survival Analysis. Tumor Suppressor Protein p53 / metabolism

Genetic Alliance. consumer health - Glioblastoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2010 Elsevier B.V. All rights reserved.

(PMID = 20441994.001).

[ISSN] 1878-5883

[Journal-full-title] Journal of the neurological sciences

[ISO-abbreviation] J. Neurol. Sci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha.

Evidence also indicates a central nervous system role for tumor necrosis factor alpha (TNF-alpha), whose expression may be increased by interferon alfa.

MedlinePlus Health Information. consumer health - Hepatitis C.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neuropsychiatry Clin Neurosci. 1991 Spring;3(2):S44-51 [1821222.001]

[Cites] Arch Gen Psychiatry. 1997 Dec;54(12):1081-8 [9400343.001]

[Cites] Acta Psychiatr Scand. 1998 Apr;97(4):309-13 [9570493.001]

[Cites] Psychiatry Res. 1998 Jun 15;79(2):163-73 [9705054.001]

[Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]

[Cites] Brain Behav Immun. 1999 Jun;13(2):175-86 [10373280.001]

[Cites] Adv Exp Med Biol. 1999;461:117-27 [10442171.001]

[Cites] J Clin Psychiatry. 2005 Jan;66(1):41-8 [15669887.001]

[Cites] J Affect Disord. 2005 Feb;84(2-3):117-25 [15708408.001]

[Cites] World J Gastroenterol. 2005 Mar 28;11(12):1769-74 [15793861.001]

[Cites] J Clin Psychiatry. 2005 Aug;66(8):1050-7 [16086622.001]

[Cites] Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):215-22 [16133740.001]

[Cites] Neurol Res. 2005 Oct;27(7):679-84 [16197804.001]

[Cites] AIDS. 2005 Oct;19 Suppl 3:S174-8 [16251815.001]

[Cites] J Autoimmun. 2005 Sep;25(2):150-4 [16046099.001]

[Cites] Arch Gen Psychiatry. 2005 Dec;62(12):1377-84 [16330726.001]

[Cites] Obes Res. 2005 Dec;13(12):2122-31 [16421346.001]

[Cites] Curr Opin Psychiatry. 2006 Jan;19(1):1-8 [16612171.001]

[Cites] Nature. 2006 Apr 20;440(7087):1054-9 [16547515.001]

[Cites] J Affect Disord. 2006 May;92(1):19-33 [16635528.001]

[Cites] J Neurosci. 2006 May 24;26(21):5709-19 [16723527.001]

[Cites] J Hum Genet. 2006;51(8):677-85 [16865291.001]

[Cites] Psychosomatics. 2007 May-Jun;48(3):223-9 [17478591.001]

[Cites] Eur J Gastroenterol Hepatol. 2007 Aug;19(8):639-46 [17625432.001]

[Cites] J Psychosom Res. 2007 Aug;63(2):131-5 [17662748.001]

[Cites] Int Rev Neurobiol. 2007;82:247-63 [17678965.001]

[Cites] Biol Psychiatry. 2007 Sep 1;62(5):536-40 [17300755.001]

[Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]

[Cites] Mol Psychiatry. 2002;7(9):942-7 [12399946.001]

[Cites] Mol Psychiatry. 2002;7(9):1023-9 [12399958.001]

[Cites] Brain Behav Immun. 2002 Oct;16(5):569-74 [12401470.001]

[Cites] Brain Behav Immun. 2002 Dec;16(6):675-84 [12480498.001]

[Cites] Psychosomatics. 2003 Mar-Apr;44(2):104-12 [12618532.001]

[Cites] J Clin Psychiatry. 2003 Jun;64(6):708-14 [12823087.001]

[Cites] Biol Psychiatry. 2003 Jul 1;54(1):34-9 [12842306.001]

[Cites] Psychiatr Genet. 2003 Sep;13(3):179-81 [12960751.001]

[Cites] Psychiatry Res. 2004 Jan 30;125(1):65-8 [14967554.001]

[Cites] Eur J Immunogenet. 2004 Feb;31(1):15-9 [15009176.001]

[Cites] J Affect Disord. 2004 Mar;78(3):273-7 [15013254.001]

[Cites] Psychosomatics. 2004 Mar-Apr;45(2):176 [15016930.001]

[Cites] Hum Immunol. 2004 Apr;65(4):347-51 [15120189.001]

[Cites] Psychoneuroendocrinology. 2004 Oct;29(9):1119-28 [15219635.001]

[Cites] J Affect Disord. 2008 Apr;107(1-3):293-8 [17850879.001]

[Cites] Brain Behav Immun. 2008 May;22(4):573-89 [18191534.001]

[Cites] Psychopharmacology (Berl). 2008 May;197(4):629-35 [18274729.001]

[Cites] Arthritis Rheum. 2008 May;58(5):1258-63 [18438841.001]

[Cites] Neuropsychobiology. 2008;57(1-2):88-94 [18515978.001]

[Cites] Psychopharmacology (Berl). 2008 Aug;199(2):231-44 [18491079.001]

[Cites] Mol Psychiatry. 2008 Aug;13(8):800-12 [18504423.001]

[Cites] Compr Psychiatry. 2008 Sep-Oct;49(5):469-75 [18702932.001]

[Cites] Biol Psychiatry. 2008 Sep 15;64(6):476-83 [18514165.001]

[Cites] Neurobiol Dis. 2008 Oct;32(1):125-32 [18672064.001]

[Cites] HIV Med. 2008 Oct;9(8):677-80 [18631256.001]

[Cites] Neuropsychobiology. 2008;58(2):71-80 [18832862.001]

[Cites] Natl Med J India. 2008 May-Jun;21(3):120-2 [19004142.001]

[Cites] Psychiatry Clin Neurosci. 2006 Oct;60(5):611-5 [16958946.001]

[Cites] J Neurosci. 2006 Sep 20;26(38):9703-12 [16988041.001]

[Cites] Aliment Pharmacol Ther. 2006 Oct 15;24(8):1223-30 [17014581.001]

[Cites] Brain Behav Immun. 2006 Nov;20(6):507-14 [16938427.001]

[Cites] Brain Res. 2006 Nov 20;1120(1):64-73 [17022949.001]

[Cites] Neuropsychopharmacology. 2006 Dec;31(12):2619-26 [16823390.001]

[Cites] J Psychiatr Res. 2007 Apr-Jun;41(3-4):326-31 [16870211.001]

[Cites] J Psychosom Res. 2007 Feb;62(2):207-14 [17270579.001]

[Cites] J Am Acad Child Adolesc Psychiatry. 2007 Mar;46(3):309-22 [17314717.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G779-84 [17170025.001]

[Cites] Eur Neuropsychopharmacol. 2007 May-Jun;17(6-7):410-6 [17187964.001]

[Cites] Brain Behav Immun. 2007 May;21(4):374-83 [17360153.001]

[Cites] Gastroenterology. 2007 Apr;132(4):1279-86 [17408646.001]

[Cites] Bipolar Disord. 2007 Sep;9(6):596-602 [17845274.001]

[Cites] J Viral Hepat. 2007 Nov;14(11):788-96 [17927615.001]

[Cites] Mol Psychiatry. 2007 Nov;12(11):988-1000 [17457312.001]

[Cites] Br J Dermatol. 2007 Dec;157(6):1275-7 [17916204.001]

[Cites] J Clin Gastroenterol. 2008 Jan;42(1):92-6 [18097297.001]

[Cites] Psychoneuroendocrinology. 2008 Jan;33(1):68-76 [17988804.001]

[Cites] Neurosci Lett. 2008 Jan 17;430(3):264-8 [18063307.001]

[Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):445-50 [17976882.001]

[Cites] Mol Immunol. 2008 Mar;45(6):1682-92 [17996942.001]

[Cites] Parkinsonism Relat Disord. 2008 Dec;14(8):636-40 [18362084.001]

[Cites] Brain Res. 2009 Jan 9;1247:178-81 [18992723.001]

[Cites] Am J Gastroenterol. 2008 Dec;103(12):3132-41 [18853973.001]

[Cites] J Psychiatr Res. 2009 Jan;43(4):471-6 [18640689.001]

[Cites] Psychiatry Clin Neurosci. 2009 Feb;63(1):50-5 [19154212.001]

[Cites] Biol Psychiatry. 2009 Feb 15;65(4):344-8 [18801474.001]

[Cites] Respir Med. 2009 Mar;103(3):386-92 [19022640.001]

[Cites] J Physiol Pharmacol. 2008 Dec;59 Suppl 6:607-14 [19218687.001]

[Cites] J Neurosci. 2009 Apr 1;29(13):4200-9 [19339614.001]

[Cites] Emotion. 2009 Jun;9(3):385-96 [19485616.001]

[Cites] Brain Behav Immun. 2009 Nov;23(8):1109-16 [19615438.001]

[Cites] CNS Spectr. 2009 Aug;14(8):419-25 [19890236.001]

[Cites] Mol Psychiatry. 2009 Dec;14(12):1095-104 [18458677.001]

[Cites] Psychiatry Res. 2010 May 15;177(1-2):240-5 [20381876.001]

[Cites] Am J Med. 1999 Dec 27;107(6B):2S-9S [10653448.001]

[Cites] Cytokine. 2000 Feb;12(2):110-9 [10671295.001]

[Cites] J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):469-76 [10761349.001]

[Cites] Science. 2000 Jul 28;289(5479):591-4 [10915615.001]

[Cites] Ann N Y Acad Sci. 2000;917:4-18 [11268367.001]

[Cites] Psychiatr Genet. 2000 Dec;10(4):195-8 [11324946.001]

[Cites] Genes Immun. 2001 Apr;2(2):105-9 [11393654.001]

[Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]

[Cites] J Viral Hepat. 2002 Mar;9(2):84-100 [11876790.001]

[Cites] Science. 2002 Mar 22;295(5563):2282-5 [11910117.001]

[Cites] Eur J Neurosci. 2002 Mar;15(6):1061-76 [11918665.001]

[Cites] Neuropsychopharmacology. 2002 May;26(5):643-52 [11927189.001]

[Cites] Hum Mol Genet. 2002 May 15;11(11):1281-9 [12019209.001]

[Cites] Genes Immun. 2004 Aug;5(5):315-29 [14973548.001]

[Cites] Psychiatry Clin Neurosci. 2004 Oct;58(5):480-6 [15482578.001]

(PMID = 20661026.001).

[ISSN] 1537-162X

[Journal-full-title] Clinical neuropharmacology

[ISO-abbreviation] Clin Neuropharmacol

[Language] ENG

[Grant] United States / NIMH NIH HHS / MH / K23 MH074012; United States / NIMH NIH HHS / MH / MH074012-05; United States / NIMH NIH HHS / MH / K23 MH074012-05

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / SLC6A4 protein, human; 0 / Serotonin Plasma Membrane Transport Proteins; 0 / Tumor Necrosis Factor-alpha; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b

[Other-IDs] NLM/ NIHMS203707; NLM/ PMC2911643

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Protein biomarker identification in the CSF of patients with CNS lymphoma.

PURPOSE: Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease.

We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.

METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients.

ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.

We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.

[MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]

[Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]

[Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]

[Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]

[Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]

[Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]

[Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]

[Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]

[Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]

[Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]

[Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]

[Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]

[Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]

[Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]

[Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]

[Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]

[Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]

[Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]

[Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]

[Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]

[CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]

(PMID = 18056677.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / K23 CA100291

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III

[Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.

In primary central nervous system diffuse large B-cell lymphomas (PCNS DLBCLs), the pathogenetic role of ATM mutation has not been investigated.

OBJECTIVE: To investigate ATM protein expression in PCNS DLBCLs, in comparison with that in non-central nervous system (non-CNS) DLBCLs and to study the relationship of ATM protein loss with several clinicopathologic parameters.

DESIGN: This study included 42 cases of PCNS DLBCL and 33 cases of non-CNS DLBCL from immunocompetent patients.

RESULTS: The loss of ATM expression was statistically more frequent in PCNS DLBCLs (21/42 cases [50.0%]) than in non-CNS DLBCLs (0/33 cases [0.0%]; P < .001).

CONCLUSIONS: Our results suggest that the ATM protein is more strongly correlated with PCNS DLBCL lymphomagenesis than with non-CNS DLBCLs, especially in germinal center B-cell-like subtypes demonstrating low Ki-67 labeling indexes and low Bcl-2 expression.

[MeSH-major] Cell Cycle Proteins / metabolism. Central Nervous System Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Serine-Threonine Kinases / metabolism. Tumor Suppressor Proteins / metabolism

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ataxia Telangiectasia Mutated Proteins. Child. Child, Preschool. Epstein-Barr Virus Infections / diagnosis. Female. Humans. In Situ Hybridization. Male. Middle Aged. Prognosis. RNA, Messenger / analysis. RNA-Binding Proteins / genetics. Ribosomal Proteins / genetics

Genetic Alliance. consumer health - Ataxia.

Genetic Alliance. consumer health - Ataxia Telangiectasia.

Genetic Alliance. consumer health - B-Cell Lymphomas.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17516749.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / Tumor Suppressor Proteins; 135844-68-7 / RPL22 protein, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Nestin was originally identified as a class VI intermediate filament protein that is expressed in stem cells and progenitor cells in the mammalian CNS during development.

This protein is replaced in the adult organism by other intermediate filament proteins; however, nestin may be re-expressed under certain pathological conditions such as ischemia, inflammation, brain injury, and neoplastic transformation.

Nestin has been detected in many kinds of tumors, especially in tumors derived from the CNS.

Co-expression of nestin and the CD133 surface molecule is considered to be a marker for cancer stem cells in neurogenic tumors.

METHODS: Using immunodetection methods, we examined nestin in tumor tissue samples from 18 patients with osteosarcomas.

We also successfully established permanent cell lines from the tumor tissue of 4 patients and immunodetection of nestin and CD133 was performed on these cell lines.

RESULTS: Nestin-positive tumor cells were immunohistochemically detected in all of the examined osteosarcomas, but the proportion of these cells that were positively stained as well as the intensity of staining varied.

Nestin-positive cells were rarely observed in 2 tumor samples, and the remaining 16 tumor samples showed various nestin expression patterns ranging from very sporadic occurrence to an overwhelming proportion of cells with strong positive staining.

Three of the established osteosarcoma cell lines were demonstrated to be nestin-positive, and only one cell line showed no expression of nestin; this finding corresponds with the rare occurrence of nestin-positive cells in the respective tumor sample.

CONCLUSION: Our results represent the first evidence of nestin expression in osteosarcomas and suggest the possible occurrence of cells with a stem-like phenotype in these tumors.

[MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Child. Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Male. Middle Aged. Nestin

Genetic Alliance. consumer health - Osteosarcoma.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Histopathology. 2006 Apr;48(5):536-45 [16623779.001]

[Cites] J Neurosci. 1985 Dec;5(12):3310-28 [4078630.001]

[Cites] Acta Neuropathol. 2006 May;111(5):475-82 [16598485.001]

[Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]

[Cites] J Pathol. 2006 Jul;209(3):287-97 [16770755.001]

[Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):1004-11 [17021405.001]

[Cites] Indian J Med Res. 2006 Sep;124(3):269-80 [17085830.001]

[Cites] Mol Cancer. 2006;5:67 [17140455.001]

[Cites] Cell Res. 2006 Dec;16(12):909-15 [17088899.001]

[Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]

[Cites] Cell Res. 2007 Jan;17(1):3-14 [17179981.001]

[Cites] Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):92-7 [17287174.001]

[Cites] Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9 [17307142.001]

[Cites] Mol Cancer. 2007;6:26 [17407576.001]

[Cites] Mod Pathol. 2007 Jul;20(7):734-41 [17464317.001]

[Cites] J Clin Pathol. 2008 Apr;61(4):467-73 [17873113.001]

[Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]

[Cites] Am J Pathol. 2001 Mar;158(3):817-23 [11238030.001]

[Cites] Stem Cells. 2001;19(5):419-24 [11553850.001]

[Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]

[Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]

[Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]

[Cites] Int J Oncol. 2002 Oct;21(4):775-85 [12239616.001]

[Cites] Neurosci Res. 2002 Oct;44(2):207-12 [12354635.001]

[Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]

[Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]

[Cites] J Cell Sci. 1992 Oct;103 ( Pt 2):589-97 [1478958.001]

[Cites] Cancer Res. 1994 Jan 15;54(2):354-6 [8275467.001]

[Cites] Neuron. 1994 Jan;12(1):11-24 [8292356.001]

[Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]

[Cites] Brain Res Dev Brain Res. 1995 Jan 14;84(1):109-29 [7720210.001]

[Cites] Lab Invest. 1996 Jan;74(1):188-98 [8569181.001]

[Cites] Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):913-25 [9353831.001]

[Cites] Pediatr Res. 1998 Mar;43(3):386-92 [9505279.001]

[Cites] Curr Opin Cell Biol. 2004 Dec;16(6):708-12 [15530785.001]

[Cites] Lab Invest. 2004 Dec;84(12):1581-92 [15502861.001]

[Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]

[Cites] J Neurooncol. 2005 Aug;74(1):1-8 [16078101.001]

[Cites] Cell Prolif. 2005 Dec;38(6):423-33 [16300654.001]

[Cites] Folia Histochem Cytobiol. 2005;43(4):175-81 [16382880.001]

[Cites] Histopathology. 2006 Mar;48(4):424-30 [16487364.001]

[Cites] BMC Cancer. 2006;6:32 [16457706.001]

[Cites] Am J Surg Pathol. 2003 Jul;27(7):1008-12 [12826895.001]

[Cites] Exp Mol Med. 2004 Feb 29;36(1):52-6 [15031671.001]

[Cites] J Biol Chem. 2004 Jul 2;279(27):27994-9 [15117961.001]

[Cites] Mod Pathol. 2006 May;19(5):659-68 [16528378.001]

(PMID = 18925963.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Peptides

[Other-IDs] NLM/ PMC2588620

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas.

Hemangiopericytomas (HPC) of the central nervous system (CNS) are uncommon dural-based tumors that mimic meningiomas clinically and radiologically.

Because there are few reports about these tumors from India, we aimed to study the clinico-pathological and immunohistochemical features of CNS HPC.

During 2000 to 2008 all 23 patients diagnosed with HPC of CNS at our Institution were reviewed in the study (11 males and 12 females, mean age of 46 years).

There were 14 patients with grade II and nine with grade III tumors.

Immunohistochemistry with antibodies to epithelial membrane antigen (EMA), vimentin, S-100, CD34 and Ki-67 was done on routinely processed, paraffin-embedded sections of 20 tumors.

The mean Ki-67 labeling index was 4.25% in grade II tumors and 7.8% in grade III tumors.

[MeSH-major] Central Nervous System Neoplasms / pathology. Hemangiopericytoma / pathology

[MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / pathology. Meningioma / pathology. Middle Aged. Tomography, X-Ray Computed. Young Adult

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2009 Elsevier Ltd. All rights reserved.

(PMID = 20167500.001).

[ISSN] 1532-2653

[Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

[ISO-abbreviation] J Clin Neurosci

[Language] eng

[Publication-type] Journal Article

[Publication-country] Scotland

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Brain tumors: from childhood through adolescence into adulthood.

Clinical care is currently divided into adult or pediatric care; adolescent patients require specific expertise that most clinical practices do not have.

When illness coincides with the adolescent transition, the health system is severely challenged.

Health systems historically have varied widely in the age they choose for allocating an individual to the adult model of health care.

Tumors of the CNS complicate the difficult adjustments required in adolescents and young adults by virtue of their morbidity, complex treatment, and prognosis.

Some brain tumors are unique to children, some occur predominantly in adults, and others peak in adolescence.

Delays in the diagnosis of brain tumors can occur at any age but are particularly common in adolescence because of difficulties of accessing health systems, the difficulties of discriminating pathologic from typical adolescent behavioral characteristics, and changing endocrine function.

This article will discuss the changing brain tumor profile of children, adolescents, and adults, with a focus on our limited understanding of the adolescent/young adult transition period.

[MeSH-major] Brain Neoplasms / diagnosis

[MeSH-minor] Adolescent. Adolescent Medicine. Adult. Brain / growth & development. Child. Continuity of Patient Care. Glioma / diagnosis. Glioma / therapy. Humans. Medulloblastoma / diagnosis. Medulloblastoma / therapy. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20458039.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1.

Although the pathogenesis of primary central nervous system lymphoma (PCNSL) remains unclear, it is hypothesized that specific chemokine-chemokine receptor interactions may attract malignant B lymphocytes into the CNS.

Tumor cells also stained positively for CXCR4.

[MeSH-major] B-Lymphocytes / metabolism. Brain Neoplasms / metabolism. Chemokines, CXC / biosynthesis. Lymphoma, B-Cell / metabolism

[MeSH-minor] Adult. Aged. Aged, 80 and over. Chemokine CCL20. Chemokine CXCL12. Chemokines, CC / biosynthesis. Female. Humans. Immunohistochemistry. Macrophage Inflammatory Proteins / biosynthesis. Male. Middle Aged. Receptors, CXCR4 / biosynthesis

Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

Genetic Alliance. consumer health - Primary malignant lymphoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17369141.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Grant] United States / NEI NIH HHS / EY / EY014909

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / CCL20 protein, human; 0 / CXCL12 protein, human; 0 / Chemokine CCL20; 0 / Chemokine CXCL12; 0 / Chemokines, CC; 0 / Chemokines, CXC; 0 / Macrophage Inflammatory Proteins; 0 / Receptors, CXCR4

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Solitary primary melanocytic tumors of the central nervous system (CNS) represent a spectrum of lesions ranging from well-differentiated melanocytoma to melanoma.

Only a minority of melanocytic tumors correspond to lesions of intermediate-grade malignancy, whose biological behavior and outcome remain undetermined.

The MIB-1/Ki-67 labeling index may have potential prognostic value in helping the clinician to predict an aggressive clinical behavior and/or malignant progression for primary melanocytic neoplasms of the CNS.

[MeSH-major] Melanoma / pathology. Meningeal Neoplasms / pathology. Nevus of Ota / pathology

[MeSH-minor] Adult. Humans. Male. Nevus, Pigmented / surgery. Radiography. Tomography Scanners, X-Ray Computed

Genetic Alliance. consumer health - Nevus.

MedlinePlus Health Information. consumer health - Melanoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Surg Neurol. 2003 Mar;59(3):200-10 [12681556.001]

[Cites] J Neurosurg. 2004 Sep;101(3):528-31 [15352613.001]

[Cites] J Neuroradiol. 2005 Jan;32(1):59-62 [15798616.001]

[Cites] Am J Surg Pathol. 1999 Jul;23(7):745-54 [10403296.001]

[Cites] Tumori. 1980 Jun 30;66(3):405-8 [7445117.001]

[Cites] Mt Sinai J Med. 1974 Nov-Dec;41(6):774-91 [4610369.001]

[Cites] J Neurosurg. 2002 Mar;96(3):619-23 [11883852.001]

[Cites] Dermatology. 1992;185(2):146-50 [1421629.001]

[Cites] Magn Reson Med. 1995 Jun;33(6):818-26 [7651119.001]

[Cites] Neurochirurgie. 2001 May;47(2-3 Pt 1):133-6 [11404684.001]

[Cites] Brain Tumor Pathol. 2003;20(1):21-5 [14604228.001]

[Cites] Strahlenther Onkol. 2002 Jun;178(6):336-42 [12122790.001]

[Cites] Cancer. 1983 Jun 15;51(12):2304-10 [6850510.001]

[Cites] Arch Neurobiol (Madr). 1989 Mar-Apr;52(2):93-9 [2667490.001]

[Cites] Neurosurgery. 2005 Jun;56(6):E1376; discussion E1376 [15918956.001]

[Cites] Neurosurgery. 1999 Nov;45(5):1216-21 [10549940.001]

[Cites] J Neurosurg. 1987 Jan;66(1):50-7 [3783260.001]

[Cites] J Neurooncol. 2003 Sep;64(3):259-63 [14558602.001]

[Cites] Oncol Rep. 2008 Jun;19(6):1367-72 [18497938.001]

[Cites] Acta Neurochir (Wien). 2005 Mar;147(3):313-5; discussion 315 [15618991.001]

[Cites] Neurosurgery. 2005 Aug;57(2):E369; discussion E369 [16094139.001]

[Cites] Clin Radiol. 2006 Mar;61(3):294-8 [16488214.001]

[Cites] J Neurosurg Spine. 2007 May;6(5):451-4 [17542513.001]

[Cites] Neurosurgery. 1992 Nov;31(5):945-8 [1436422.001]

[Cites] Childs Nerv Syst. 2006 Jun;22(6):556-61 [16491422.001]

[Cites] Klin Monbl Augenheilkd. 1992 Jun;200(6):665-70 [1507791.001]

[Cites] J Neurosurg. 1992 Apr;76(4):705-9 [1545267.001]

[Cites] Arch Pathol Lab Med. 1995 Jun;119(6):542-6 [7605172.001]

[Cites] Cancer. 1972 Nov;30(5):1286-94 [4343293.001]

[Cites] J Neurosurg. 2001 Oct;95(2 Suppl):225-31 [11599841.001]

[Cites] NMR Biomed. 1996 Apr;9(2):65-71 [8887370.001]

[Cites] Neurology. 1993 Feb;43(2):381-6 [8437707.001]

[Cites] Childs Nerv Syst. 2009 Apr;25(4):407-10 [19139906.001]

(PMID = 19449182.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system.

Dexamethasone, a synthetic glucocorticoid, is commonly co-administered to control edema in the management of brain tumors during chemotherapy and radiotherapy.

[MeSH-major] 5'-Nucleotidase / metabolism. Anti-Inflammatory Agents / pharmacology. Brain Neoplasms / enzymology. Dexamethasone / pharmacology. Glioma / enzymology

[MeSH-minor] Adenosine Monophosphate / metabolism. Animals. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Protein Kinase C / metabolism. Purines / metabolism. Rats. Signal Transduction / drug effects. Time Factors

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Anticancer Res. 1996 Mar-Apr;16(2):805-9 [8687132.001]

[Cites] Anal Biochem. 1986 Sep;157(2):375-80 [2946250.001]

[Cites] Am J Reprod Immunol. 2005 Mar;53(3):144-52 [15727569.001]

[Cites] Vascul Pharmacol. 2005 Mar;42(4):153-62 [15820441.001]

[Cites] J Cell Physiol. 2001 Jan;186(1):19-23 [11147810.001]

[Cites] J Neurooncol. 2001 Jan;51(2):105-10 [11386406.001]

[Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]

[Cites] Drug Metab Dispos. 2006 Jun;34(6):1063-9 [16531474.001]

[Cites] Pharmacol Rev. 1998 Sep;50(3):413-92 [9755289.001]

[Cites] Pharmacol Ther. 2003 Oct;100(1):31-48 [14550503.001]

[Cites] Neurology. 1997 Jun;48(6):1704-9 [9191791.001]

[Cites] Purinergic Signal. 2006 Jun;2(2):409-30 [18404480.001]

[Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1585-8 [7979189.001]

[Cites] J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82 [15698542.001]

[Cites] Eur J Pharmacol. 1992 Oct 1;227(2):113-22 [1426027.001]

[Cites] Br J Pharmacol. 1997 Jan;120(2):273-81 [9117120.001]

[Cites] J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43 [16125621.001]

[Cites] Genes Dev. 1995 Jul 1;9(13):1608-21 [7628695.001]

[Cites] Neuroscience. 2000;96(2):417-25 [10683582.001]

[Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]

[Cites] Blood. 2003 Dec 15;102(13):4472-8 [12947007.001]

[Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32 [11124130.001]

[Cites] Oncogene. 1998 Sep 24;17(12):1567-75 [9794234.001]

[Cites] Trends Pharmacol Sci. 2006 Mar;27(3):166-76 [16487603.001]

[Cites] Apoptosis. 1999 Jun;4(3):197-211 [14634282.001]

[Cites] Melanoma Res. 2006 Jun;16(3):213-22 [16718268.001]

[Cites] BMC Cancer. 2006 Sep 23;6:226 [16995949.001]

[Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]

[Cites] Trends Pharmacol Sci. 2006 Apr;27(4):211-7 [16530853.001]

[Cites] Nucleic Acids Res. 1992 Feb 25;20(4):825-9 [1531873.001]

[Cites] Cancer Lett. 2003 Aug 20;198(2):211-8 [12957360.001]

[Cites] Biochem J. 1992 Jul 15;285 ( Pt 2):345-65 [1637327.001]

(PMID = 17453149.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Purines; 415SHH325A / Adenosine Monophosphate; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.5 / 5'-Nucleotidase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Netrin-1 regulates axon extension during embryonic development and is expressed by neurons and myelinating oligodendrocytes in the adult CNS.

To investigate the potential role of netrin-1 after spinal cord injury, we examined the expression of netrin-1 and netrin receptors after sagittal myelotomy in adult rats.

[MeSH-major] Gene Expression Regulation / physiology. Nerve Growth Factors / metabolism. Receptors, Cell Surface / metabolism. Spinal Cord Injuries / metabolism. Spinal Cord Injuries / physiopathology. Tumor Suppressor Proteins / metabolism

MedlinePlus Health Information. consumer health - Spinal Cord Injuries.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16998900.001).

[ISSN] 0360-4012

[Journal-full-title] Journal of neuroscience research

[ISO-abbreviation] J. Neurosci. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / netrin receptors; 158651-98-0 / netrin-1

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Ependymomas are common pediatric and adult CNS malignancies with a wide biologic spectrum that is often hard to predict using classic prognostic variables.

The majority of cases harbored one or more detectable genetic alterations, but we found that 4.1B gene deletions and 4.1R loss of expression were statistically more common in the pediatric vs adult, intracranial vs spinal, and grade III vs grade I/II subsets (P-values of 0.038 to <0.001).

Also, 4.1G deletions were seen in 11/27 (41%) patients who either died of disease or had residual/recurrent tumor vs 5/41 patients with no evidence of disease at last follow-up (P=0.009).

We conclude that alterations of Protein 4.1 family members are common in ependymal tumors and that specific alterations are associated with distinct clinicopathologic subsets.

[MeSH-minor] Adolescent. Adult. Aged. Blood Proteins / analysis. Blood Proteins / genetics. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Cohort Studies. Cytoskeletal Proteins / analysis. Cytoskeletal Proteins / genetics. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Microfilament Proteins. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / genetics. Middle Aged. Neurofibromin 2 / analysis. Neurofibromin 2 / genetics. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / metabolism. Spinal Cord Neoplasms / pathology. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15731777.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Blood Proteins; 0 / Cytoskeletal Proteins; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / erythrocyte membrane band 4.1 protein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiological imaging detection of tumors localized in fossa cranii posterior.

Intracranial tumors are characterized by a variety imaging aspects and their detection is always a challenge.

Clinical application of Magnetic Resonance Imaging (MRI) and Computerized Tomography has provided an earlier detection and treatment of many CNS pathologies.

The aim of this study is to estimate the role of CT and MRI in the determination of posterior fossa tumors.

RESULTS: During period 2000-2005 in UCCK-Prishtina, 368 patients were diagnosed with intracranial tumors.

Fifty-nine of them were found to have tumor localized in fossa crani posterior (FCP) without any significant difference between genders (50.8% female vs. 49.2% male, chi2 test=0.02 p=0.896).

The average age of patients with FCP tumors was 33.1 (SD +/- 22.5, rank 1-70).

Tumor types that more often were found in young's individuals were: Astrocytomas with a peak incidence in teenagers (average age was 12-year-old SD +/- 7.5, rank 3-23), next was Medulloblastomas (average age was 11-years-old, SD +/- 2.9, rank 6-16 years) and ependymomas (average age was 6.8-years-old, SD +/- 4.6, rank 1-12).

Patients with osseous tumors are characterized by older age than median (61.0, SD +/- 4.2, rank 58-64), then metastases (53.0, SD +/- 5.3, rank 45-60) and meningiomas (50.8, SD +/- 7.7, rank 38-63).

CONCLUSION: Comparing with other countries, for some types of FCP tumors, lower morbidity is shown in Kosova, with mean incidence 0.41/100,000.

The most frequent tumors in children were medulloblastomas, brainstem gliomas, astrocytomas and ependymomas whereas meningiomas and metastasis were most often found in adults.

For FCP tumors detection, MRI had 100% sensitivity, specificity and predictive positive value, whereas brain CT was characterized by 95% sensitivity, 90.4 % specificity and 91% predictive positive value.

[MeSH-major] Infratentorial Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Young Adult

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19469268.001).

[Journal-full-title] Medicinski arhiv

[ISO-abbreviation] Med Arh

[Language] eng

[Publication-type] Journal Article

[Publication-country] Bosnia and Herzegovina

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Evidence suggests that sex hormones may play a role in the tumorigenesis of meningiomas, and studies have demonstrated the expression of hormone receptors in these tumors.

Aromatase expression has been detected in several normal tissues, including neurons in the CNS, and tumor tissues.

Behavior pattern differences observed between aromatase expression, present in normal tissues and absent in meningiomas, and estrogen and androgen hormone receptors, absent in normal tissues and present in meningiomas, suggest that there is heterogeneity in modulation by sex steroids in the development of these tumors.

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Arachnoid Cysts / enzymology. Arachnoid Cysts / metabolism. Brazil. Cross-Sectional Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Odds Ratio. Sex Characteristics. Young Adult

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19703265.001).

[ISSN] 1440-1789

[Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology

[ISO-abbreviation] Neuropathology

[Language] eng

[Publication-type] Journal Article

[Publication-country] Australia

[Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 1.14.14.1 / Aromatase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term fate of neural precursor cells following transplantation into developing and adult CNS.

Successful strategies for transplantation of neural precursor cells for replacement of lost or dysfunctional CNS cells require long-term survival of grafted cells and integration with the host system, potentially for the life of the recipient.

Few studies have examined the long-term properties of transplanted neural precursor cells in the CNS, particularly in non-neurogenic regions of the adult.

The aim of the present study was to extensively characterize the fate of defined populations of neural precursor cells following transplantation into the developing and adult CNS (brain and spinal cord) for up to 15 months, including integration of graft-derived neurons with the host.

We found that in both developing and adult CNS grafted cells showed long-term survival, morphological maturation, extensive distribution and differentiation into all mature CNS cell types (neurons, astrocytes and oligodendrocytes).

Graft-derived neurons also formed synapses, as identified by electron microscopy, suggesting that transplanted neural precursor cells integrated with adult CNS.

We did not detect tumor formation, cells did not localize to unwanted locations and no pronounced immune response was present at the graft sites.

The long-term stability of neuronal-restricted precursors and glial-restricted precursors and the lack of adverse effects suggest that transplantation of lineage-restricted neural precursor cells can serve as an effective and safe replacement therapy for CNS injury and degeneration.

[MeSH-major] Cell Differentiation / physiology. Central Nervous System / physiology. Neurons / physiology. Stem Cell Transplantation / methods. Stem Cells / physiology

MedlinePlus Health Information. consumer health - Stem Cells.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[RepublishedFrom] Neuroscience. 2006 May 12;139(2):513-30 [16458439.001]

(PMID = 17120358.001).

[ISSN] 0306-4522

[Journal-full-title] Neuroscience

[ISO-abbreviation] Neuroscience

[Language] eng

[Grant] United States / NINDS NIH HHS / NS / NS 37515; United States / NINDS NIH HHS / NS / NS24707

[Publication-type] Comparative Study; Corrected and Republished Article; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Gangliosides; 0 / Immunosuppressive Agents; 0 / Nerve Tissue Proteins; 0 / Neural Cell Adhesion Molecules; 0 / ganglioside A2B5

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

AIMS: Deleted in colorectal cancer (DCC) and its ligand netrin-1 are known as axonal guidance factors, being involved in angiogenesis, migration and survival of precursor cells in the embryonic mammalian central nervous system (CNS).

So far, little is known about the distribution of those molecules in human CNS development.

Together with the data from animal experiments, our findings might indicate also an important role for DCC and netrin-1 in human foetal CNS development.

[MeSH-major] Brain / embryology. Brain Chemistry / physiology. Nerve Growth Factors / biosynthesis. Receptors, Cell Surface / biosynthesis. Tumor Suppressor Proteins / biosynthesis

[MeSH-minor] Adult. Brain Stem / metabolism. Cerebellum / metabolism. Cerebral Cortex / metabolism. Choroid Plexus / metabolism. Ependyma / cytology. Ependyma / metabolism. Female. Fetal Development. Fetus / metabolism. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Pregnancy

Genetic Alliance. consumer health - Colorectal Cancer.

Genetic Alliance. consumer health - Colorectal cancer 1.

Genetic Alliance. consumer health - Brain Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 The Authors. Neuropathology and Applied Neurobiology © 2010 British Neuropathological Society.

(PMID = 20609112.001).

[ISSN] 1365-2990

[Journal-full-title] Neuropathology and applied neurobiology

[ISO-abbreviation] Neuropathol. Appl. Neurobiol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / DCC protein, human; 0 / Nerve Growth Factors; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A rare case of pulmonary cryptococcal inflammatory myofibroblastic tumor diagnosed by fine needle aspiration cytology.

In a recent outbreak in British Columbia (BC), Canada, Cryptococcus gattii, a rare species of Cryptococcus, was noted to affect primarily immunocompetent hosts and cause limited pulmonary or CNS disease.

We herein report a rare case of a pulmonary inflammatory myofibroblastic tumor caused by a Cryptococcus infection, presumed to be of the gattii species, in a 20-year-old immunocompetent college student from Vancouver, BC who presented with a large lung mass.

Cryptococcal inflammatory myofibroblastic tumors have been reported, but neither in the lung nor in the setting of an immunocompetent host.

[MeSH-minor] Antifungal Agents / therapeutic use. Biopsy, Fine-Needle. Cryptococcus gattii. Female. Fluconazole / therapeutic use. Humans. Young Adult

Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

Hazardous Substances Data Bank. FLUCONAZOLE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2009 Wiley-Liss, Inc.

(PMID = 19937947.001).

[ISSN] 1097-0339

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antifungal Agents; 8VZV102JFY / Fluconazole

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Neural stem cells (NSCs) are present during embryonic development and in certain regions of the adult central nervous system (CNS).

Mobilizing adult NSCs to promote repair of injured or diseased CNS is a promising approach.

Since NSCs may give rise to brain tumor, they represent in vitro models for anti-cancer drug screening.

Important future directions that are highlighted in this review are; identification of markers for NSCs, the use of NSCs in high-throughput screens and the modelling of the central nervous development.

There is no doubt that the study of NSCs is crucial if we are to tackle the diseases of the CNS such as Parkinson's and Alzheimer's.

[MeSH-minor] Animals. Cells, Cultured. Central Nervous System / cytology. Humans. Models, Biological

MedlinePlus Health Information. consumer health - Stem Cells.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2008 Wiley-Liss, Inc.

(PMID = 19021147.001).

[ISSN] 1097-4644

[Journal-full-title] Journal of cellular biochemistry

[ISO-abbreviation] J. Cell. Biochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Number-of-references] 80

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.

BACKGROUND: High-dose methotrexate (HDMTX) (>or=3 g/m2), the cornerstone of therapy for primary CNS lymphoma (PCNSL), is commonly dosed using a measured 24 h creatinine clearance (CrCl) every 2-4 weeks.

METHODS: A retrospective analysis was performed on data from all 287 treatment cycles from the 25 patients with PCNSL who participated in a multi-center phase II clinical trial of HDMTX conducted by the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium.

[MeSH-major] Central Nervous System Neoplasms / drug therapy. Creatinine / pharmacokinetics. Kidney Function Tests / methods. Lymphoma / drug therapy. Lymphoma / urine. Methotrexate / administration & dosage

[MeSH-minor] Adult. Aged. Female. Humans. Male. Metabolic Clearance Rate. Middle Aged. Retrospective Studies

Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

MedlinePlus Health Information. consumer health - Creatinine.

MedlinePlus Health Information. consumer health - Kidney Tests.

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16972068.001).

[ISSN] 0344-5704

[Journal-full-title] Cancer chemotherapy and pharmacology

[ISO-abbreviation] Cancer Chemother. Pharmacol.

[Language] eng

[Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study

[Publication-country] Germany

[Chemical-registry-number] AYI8EX34EU / Creatinine; YL5FZ2Y5U1 / Methotrexate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor.

OBJECTIVE: The purpose of this study was to evaluate the efficacy of quantitative imaging of glucose metabolism with positron emission tomography (PET) using kinetic analysis for differentiating between high-grade glioma and central nervous system (CNS) lymphoma.

METHODS: Dynamic fluorine-18-fluorodeoxyglucose (18F-FDG)-PET scans obtained in 20 patients with high-grade glioma (World Health Organization grade III, five lesions; grade IV, 15 lesions) and in 12 patients with CNS lymphoma (16 lesions) were retrospectively reviewed.

Fourteen CNS lymphoma lesions showed an increase of K1, 16 of k3, two of k4, and 14 of CMR(Glc).

Both k3 and CMR(Glc) values (mean+/-SD) of CNS lymphoma (0.096+/-0.046 and 77.4+/-37.7, respectively) were significantly higher than those of the normal gray matter (0.059+/-0.015 and 41.3+/-9.3, respectively; P<0.007 and P<0.002, respectively).

The k3 value of CNS lymphoma was significantly higher than that of grade III (0.058+/-0.022) and grade IV (0.065+/-0.024) gliomas (P<0.03 and P<0.04, respectively).

The CMR(Glc) value of CNS lymphoma was significantly higher than that of grade III (33.8+/-7.8) and grade IV (41.5+/-23.1) gliomas (P<0.001 and P<0.004, respectively).

The value of k2 of CNS lymphoma was significantly lower than that of grade IV glioma (P<0.05).

CONCLUSION: The direct measurement of the regional rate constants by kinetic analysis might be useful for the delineation of CNS lymphoma and for differential diagnosis of high-grade glioma and CNS lymphoma.

[MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Glucose / metabolism

[MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Glioma / metabolism. Glioma / radionuclide imaging. Humans. Kinetics. Lymphoma / metabolism. Lymphoma / radionuclide imaging. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. GLUCOSE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19521265.001).

[ISSN] 1473-5628

[Journal-full-title] Nuclear medicine communications

[ISO-abbreviation] Nucl Med Commun

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.

OBJECTIVE: Nogo-A is an axon regeneration inhibitor, and its function in central nervous system (CNS) is still unknown.

The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial tumors in patients.

METHODS: Tumor tissue samples with different malignancy grade were obtained from the hospitals.

The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma).

The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in the tumors) related to the malignancy of tumor tissues was performed.

RESULTS: There was significant negative correlation between the Nogo-A expression and the morphological change of tumor tissues according to immunohistochemistry.

CONCLUSION: Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors.

[MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Myelin Proteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism

[MeSH-minor] Adult. Down-Regulation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / diagnosis. Nogo Proteins. Predictive Value of Tests

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurosci. 2002 May 1;22(9):3553-67 [11978832.001]

[Cites] J Neurosci. 2003 Jul 2;23 (13):5393-406 [12843238.001]

[Cites] Oncogene. 2001 Jul 5;20(30):3929-36 [11494121.001]

[Cites] J Mol Neurosci. 2005;25(1):1-6 [15781961.001]

[Cites] J Cell Physiol. 2003 Aug;196 (2):312-8 [12811824.001]

[Cites] Nature. 2000 Jan 27;403(6768):434-9 [10667796.001]

[Cites] J Biol Chem. 2003 May 23;278(21):19280-5 [12639960.001]

[Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]

[Cites] Cancer Res. 1998 Jan 1;58(1):149-58 [9426071.001]

[Cites] J Neurochem. 2004 Sep;90(5):1156-62 [15312170.001]

[Cites] Oncogene. 2003 Mar 6;22(9):1390-9 [12618765.001]

[Cites] Oncogene. 2000 Nov 23;19(50):5736-46 [11126360.001]

[Cites] Biochem J. 2005 Oct 15;391(Pt 2):433-40 [16095439.001]

[Cites] Oncogene. 2004 Apr 15;23(17):2977-87 [15021917.001]

[Cites] Apoptosis. 2003 Jan;8(1):5-9 [12510146.001]

(PMID = 17592524.001).

[ISSN] 1673-7067

[Journal-full-title] Neuroscience bulletin

[ISO-abbreviation] Neurosci Bull

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Singapore

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / RTN4 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.

PURPOSE: To determine retrospectively whether unenhanced computed tomographic (CT) images of the brain have added value in distinguishing tumefactive demyelinating lesions (TDLs) from primary glioma or central nervous system (CNS) lymphoma, compared with conventional contrast material-enhanced magnetic resonance (MR) images only.

Unenhanced CT and MR images in 15 patients with TDLs (seven women, eight men; mean age, 42 years; range, 27-57 years) and 48 patients with primary brain tumor (27 women, 21 men; mean age, 48 years; range, 19-70 years; 10 lymphomas, 38 gliomas) were retrospectively reviewed.

The diagnostic accuracy of MR imaging for differentiating TDLs from tumors was compared with that of MR imaging plus CT.

RESULTS: The following MR imaging features were found more frequently in patients with TDL than in those with brain tumor: incomplete rim enhancement, mixed T2-weighted iso- and hyperintensity of enhanced regions, absence of a mass effect, and absence of cortical involvement (all P values < .05).

CT hypoattenuation of MR enhanced regions was observed in 14 (93%) of 15 patients with TDL but in only two (4%) of 48 patients with tumor.

The CT attenuation of MR enhanced regions was significantly lower for patients with TDL than for those with tumor (P < .001).

CONCLUSION: Unenhanced CT plus MR imaging was more accurate for distinguishing TDLs from glioma or CNS lymphoma than contrast-enhanced MR imaging alone.

[MeSH-major] Brain Neoplasms / diagnosis. Demyelinating Diseases / diagnosis. Glioma / diagnosis. Image Enhancement / methods. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

[MeSH-minor] Adult. Contrast Media. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - Lymphoma.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19261924.001).

[ISSN] 1527-1315

[Journal-full-title] Radiology

[ISO-abbreviation] Radiology

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Contrast Media

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

PURPOSE: Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence.

PATIENTS AND METHODS: Three phase I clinical studies evaluated intracerebral CED of CB along with tumor resection.

All patients underwent tumor resection followed by a single intraparenchymal infusion (in addition to the intraparenchymal one following resection), with a portion of patients who had a preresection intratumoral infusion.

The maximum tolerated intraparenchymal concentration was 0.5 microg/mL and tumor necrosis was observed at this concentration.

CB- and procedure-related adverse events were primarily limited to the CNS.

[MeSH-major] Drug Delivery Systems / methods. Exotoxins / administration & dosage. Glioma / drug therapy. Immunotoxins / administration & dosage. Interleukin-13 / administration & dosage. Supratentorial Neoplasms / drug therapy

[MeSH-minor] Adult. Aged. Catheterization. Convection. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tissue Distribution

Genetic Alliance. consumer health - Glioma.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

SciCrunch. DrugBank: Data: Chemical .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17327604.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial, Phase I; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease.

Hemangioblastomas are rare CNS tumors, which are mostly located in the posterior fossa or spinal cord and occasionally in spinal nerves.

They can occur sporadically or as a component tumor of von Hippel-Lindau (VHL) disease, an autosomal dominant tumor syndrome.

[MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Hemangioblastoma / pathology. Hemangioblastoma / surgery. Neurosurgical Procedures / methods. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / pathology. von Hippel-Lindau Disease / surgery

[MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.

(PMID = 20229452.001).

[ISSN] 1868-4912

[Journal-full-title] Central European neurosurgery

[ISO-abbreviation] Cent Eur Neurosurg

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature.

Desmoplastic small round cell tumor (DSRCT) is a malignant tumor often involving the abdominal and/or pelvic peritoneum.

Only one fully documented example has arisen in the central nervous system (CNS).

In conclusion, CNS DSRCT follows a similar aggressive course as do peritoneal examples.

Although rare, DSRCT warrants consideration in the differential diagnosis of "malignant small blue cell tumors" of the CNS.

[MeSH-major] Carcinoma, Small Cell / pathology. Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology

[MeSH-minor] Adult. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Surg Pathol. 1992 Oct;16(10):998-1006 [1384373.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] Am J Surg Pathol. 1998 Nov;22(11):1303-13 [9808123.001]

[Cites] Am J Surg Pathol. 1990 Jul;14(7):633-42 [2356923.001]

[Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]

[Cites] Diagn Mol Pathol. 1998 Feb;7(1):24-8 [9646031.001]

[Cites] Am J Surg Pathol. 1996 Jan;20(1):112-7 [8540602.001]

[Cites] Hum Pathol. 1997 Apr;28(4):502-9 [9104953.001]

[Cites] Cancer Cell. 2002 Dec;2(6):497-505 [12498718.001]

[Cites] Arch Pathol Lab Med. 2006 May;130(5):728-32 [16683894.001]

[Cites] Hum Pathol. 1992 Apr;23(4):454-64 [1563748.001]

[Cites] Arch Pathol Lab Med. 1989 Sep;113(9):1019-29 [2505732.001]

[Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]

[Cites] Am J Surg Pathol. 1989 May;13(5):413-21 [2469334.001]

[Cites] Nature. 1990 Jul 12;346(6280):194-7 [2164159.001]

[Cites] Am J Surg Pathol. 1995 Jun;19(6):659-65 [7755152.001]

[Cites] Diagn Mol Pathol. 2005 Mar;14(1):23-8 [15714060.001]

[Cites] Am J Surg Pathol. 1999 Nov;23(11):1408-13 [10555010.001]

[Cites] Cancer Genet Cytogenet. 1993 Aug;69(1):17-21 [8374894.001]

[Cites] Exp Cell Res. 2001 Mar 10;264(1):74-99 [11237525.001]

[Cites] Acta Cytol. 1995 Mar-Apr;39(2):377-8 [7887076.001]

[Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]

[Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Acta Cytol. 1993 Jan-Feb;37(1):77-82 [7679537.001]

[Cites] Semin Diagn Pathol. 1996 Aug;13(3):204-12 [8875710.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32 [7862627.001]

[Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]

[Cites] Virchows Arch. 1998 Feb;432(2):135-41 [9504858.001]

[Cites] Mod Pathol. 1999 Jul;12(7):729-34 [10430278.001]

[Cites] Ultrastruct Pathol. 2000 Sep-Oct;24(5):333-7 [11071572.001]

[Cites] Hum Pathol. 1999 Apr;30(4):430-5 [10208465.001]

[Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]

[Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(3):207-14 [1900966.001]

[Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]

[Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]

[Cites] Gynecol Oncol. 2000 Oct;79(1):124-8 [11006044.001]

[Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1226-8 [12296765.001]

[Cites] Semin Cancer Biol. 2005 Jun;15(3):197-205 [15826834.001]

[Cites] Semin Diagn Pathol. 2003 Feb;20(1):25-45 [12693673.001]

[Cites] Pediatr Blood Cancer. 2008 Oct;51(4):545-8 [18561179.001]

(PMID = 19263077.001).

[ISSN] 1432-2307

[Journal-full-title] Virchows Archiv : an international journal of pathology

[ISO-abbreviation] Virchows Arch.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Primary melanocytic neoplasms of the central nervous system (CNS) are uncommon neoplasms derived from melanocytes that normally can be found in the leptomeninges.

Characteristic genetic alterations in this group of neoplasms have not yet been identified.

Using direct sequencing, we investigated 19 primary melanocytic lesions of the CNS (12 melanocytomas, 3 intermediate-grade melanocytomas, and 4 melanomas) for hotspot oncogenic mutations commonly found in melanocytic tumors of the skin (BRAF, NRAS, and HRAS genes) and uvea (GNAQ gene).

Somatic mutations in the GNAQ gene at codon 209, resulting in constitutive activation of GNAQ, were detected in 7/19 (37%) tumors, including 6/12 melanocytomas, 0/3 intermediate-grade melanocytomas, and 1/4 melanomas.

These GNAQ-mutated tumors were predominantly located around the spinal cord (6/7).

One melanoma carried a BRAF point mutation that is frequently found in cutaneous melanomas (c.1799 T>A, p.V600E), raising the question whether this is a metastatic rather than a primary tumor.

We conclude that somatic mutations in the GNAQ gene at codon 209 are a frequent event in primary melanocytic neoplasms of the CNS.

This finding provides new insight in the pathogenesis of these lesions and suggests that GNAQ-dependent mitogen-activated kinase signaling is a promising therapeutic target in these tumors.

The prognostic and predictive value of GNAQ mutations in primary melanocytic lesions of the CNS needs to be determined in future studies.

[MeSH-major] Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / pathology. GTP-Binding Protein alpha Subunits / genetics. Melanocytes / pathology. Melanoma / pathology. Mutation / genetics

[MeSH-minor] Adult. Aged. Codon / genetics. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Genes, ras / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins B-raf / genetics. Retrospective Studies. Tissue Fixation

MedlinePlus Health Information. consumer health - Melanoma.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2009 May 1;27(13):2290-1 [19349541.001]

[Cites] Br J Cancer. 2009 Sep 1;101(5):813-5 [19654573.001]

[Cites] PLoS One. 2009;4(8):e6833 [19718445.001]

[Cites] Nature. 1999 Dec 2;402(6761):496-501 [10591209.001]

[Cites] Annu Rev Biochem. 2000;69:795-827 [10966476.001]

[Cites] Clin Cancer Res. 2002 Nov;8(11):3468-74 [12429636.001]

[Cites] Cancer Res. 2003 Sep 15;63(18):5761-6 [14522897.001]

[Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]

[Cites] J Invest Dermatol. 2003 Nov;121(5):1160-2 [14708620.001]

[Cites] Int J Cancer. 2004 Sep 20;111(5):705-10 [15252839.001]

[Cites] Nat Genet. 2004 Sep;36(9):961-8 [15322542.001]

[Cites] Nat Genet. 2004 Sep;36(9):935-6 [15340429.001]

[Cites] Neurosurgery. 1981 Jan;8(1):26-30 [7207769.001]

[Cites] J Invest Dermatol. 1984 Mar;82(3):235-8 [6699426.001]

[Cites] J Neurosurg. 1987 Jun;66(6):948 [3572529.001]

[Cites] Annu Rev Biochem. 1987;56:779-827 [3304147.001]

[Cites] Cancer. 1988 May 1;61(9):1926-34 [3355984.001]

[Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):747-55 [1869648.001]

[Cites] Neurology. 1993 Feb;43(2):381-6 [8437707.001]

[Cites] Science. 1993 Dec 17;262(5141):1895-901 [8266082.001]

[Cites] Neurosurgery. 1994 Mar;34(3):533-7; discussion 637 [8190231.001]

[Cites] Pathologica. 1997 Apr;89(2):168-74 [9411364.001]

[Cites] Am J Surg Pathol. 1999 Jul;23(7):745-54 [10403296.001]

[Cites] Acta Neurochir (Wien). 2005 Mar;147(3):313-5; discussion 315 [15618991.001]

[Cites] Melanoma Res. 2006 Apr;16(2):97-103 [16567964.001]

[Cites] Melanoma Res. 2006 Aug;16(4):267-73 [16845322.001]

[Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]

[Cites] Hum Mutat. 2007 Jun;28(6):578-88 [17295241.001]

[Cites] Curr Opin Oncol. 2008 Mar;20(2):183-9 [18300768.001]

[Cites] J Neurosurg Spine. 2008 Jul;9(1):48-54 [18590410.001]

[Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4 [18719078.001]

[Cites] Nature. 2009 Jan 29;457(7229):599-602 [19078957.001]

(PMID = 19936769.001).

[ISSN] 1432-0533

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / GNAQ protein, human; 0 / GTP-Binding Protein alpha Subunits; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.

INTRODUCTION: To evaluate the incidence of central nervous system (CNS) involvement in patients with breast cancer treated with a taxane-based chemotherapy regimen and to determine predictive factors for CNS relapse.

METHODS: The medical files of patients with early breast cancer (n = 253) or advanced stage breast cancer (n = 239) as well of those with other solid tumors (n = 336) treated with or without a taxane-based chemotherapy regimen during a 42-month period were reviewed.

HER2/neu overexpression was identified by immunohistochemistry, whereas cytokeratin 19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in the peripheral blood were identified by real-time PCR.

RESULTS: The incidence of CNS relapse was similar in patients suffering from breast cancer or other solid tumors (10.4% and 11.4%, respectively; P = 0.517).

The incidence of CNS relapse was significantly higher in breast cancer patients with advanced disease (P = 0.041), visceral disease and bone disease (P = 0.036), in those who were treated with a taxane-containing regimen (P = 0.024), in those with HER2/neu-overexpressing tumors (P = 0.022) and, finally, in those with detectable CK-19 mRNA-positive CTCs (P = 0.008).

Multivariate analysis revealed that the stage of disease (odds ratio, 0.23; 95% confidence interval, 0.007-0.23; P = 0.0001), the HER2/neu status (odds ratio, 29.4; 95% confidence interval, 7.51-101.21; P = 0.0001) and the presence of CK-19 mRNA-positive CTCs (odds ratio, 8.31; 95% confidence interval, 3.97-12.84; P = 0.001) were independent predictive factors for CNS relapse.

CONCLUSION: CNS relapses are common among breast cancer patients treated with a taxane-based chemotherapy regimen, patients with HER2/neu-positive tumor and patients with CK-19 mRNA-positive CTCs.

[MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / physiopathology. Central Nervous System Neoplasms / physiopathology. Neoplastic Cells, Circulating

[MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Keratin-19. Middle Aged. Neoplasm Staging. Predictive Value of Tests. RNA, Messenger. Receptor, ErbB-2 / biosynthesis. Taxoids / therapeutic use

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 2000 Feb 24;342(8):525-33 [10684910.001]

[Cites] Ann Oncol. 2005 Nov;16(11):1772-7 [16150805.001]

[Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]

[Cites] Ann Oncol. 2001 Mar;12(3):353-6 [11332148.001]

[Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]

[Cites] Lancet Oncol. 2002 Jan;3(1):53-7 [11905606.001]

[Cites] J Clin Oncol. 2002 Aug 15;20(16):3404-12 [12177100.001]

[Cites] J Clin Oncol. 2002 Oct 1;20(19):4130-3 [12351617.001]

[Cites] J Clin Invest. 2002 Nov;110(9):1309-18 [12417570.001]

[Cites] Cancer. 2003 Jun 15;97(12):2972-7 [12784331.001]

[Cites] Ann Oncol. 2003 Jun;14(6):849-55 [12796021.001]

[Cites] Ann Oncol. 2003 Jul;14(7):1072-7 [12853349.001]

[Cites] Clin Cancer Res. 2003 Nov 1;9(14):5145-51 [14613993.001]

[Cites] Br J Cancer. 2004 Aug 16;91(4):639-43 [15266327.001]

[Cites] Adv Neurol. 1978;19:579-92 [570349.001]

[Cites] Cancer. 1979 Nov;44(5):1913-8 [498057.001]

[Cites] Cancer. 1981 Feb 1;47(3):554-60 [7226005.001]

[Cites] Eur J Cancer. 1981 Apr;17(4):449-53 [7308254.001]

[Cites] Cancer. 1983 Dec 15;52(12):2349-54 [6640506.001]

[Cites] Cancer Chemother Pharmacol. 1994;34(6):465-71 [7923556.001]

[Cites] Ann Oncol. 1994 Dec;5(10):951-3 [7696168.001]

[Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]

[Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24 [10393719.001]

[Cites] Ann Oncol. 2004 Nov;15(11):1640-4 [15520065.001]

[Cites] Clin Cancer Res. 2004 Dec 15;10(24):8185-94 [15623593.001]

[Cites] QJM. 2000 Sep;93(9):611-5 [10984556.001]

(PMID = 16846533.001).

[ISSN] 1465-542X

[Journal-full-title] Breast cancer research : BCR

[ISO-abbreviation] Breast Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Keratin-19; 0 / RNA, Messenger; 0 / Taxoids; EC 2.7.10.1 / Receptor, ErbB-2

[Other-IDs] NLM/ PMC1779464

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MEGF9: a novel transmembrane protein with a strong and developmentally regulated expression in the nervous system.

MEGF9 [multiple EGF (epidermal growth factor)-like-domains 9], a novel transmembrane protein with multiple EGF-like repeats, is predominantly expressed in the developing and adult CNS (central nervous system) and PNS (peripheral nervous system).

[MeSH-major] Central Nervous System / metabolism. Gene Expression Regulation, Developmental. Membrane Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Peripheral Nervous System / metabolism

[MeSH-minor] Amino Acid Sequence. Animals. Epidermal Growth Factor / genetics. Humans. Keratinocytes / metabolism. Mice. Molecular Sequence Data. Protein Processing, Post-Translational. Protein Structure, Tertiary. Rats. Sequence Alignment. Skin / cytology. Tongue / cytology. Tumor Cells, Cultured

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 1991 May 25;266(15):9678-86 [2033060.001]

[Cites] Pediatr Res. 2005 May;57(5 Pt 2):104R-109R [15817497.001]

[Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4037-41 [8483919.001]

[Cites] Hum Mutat. 1999;14(5):394-400 [10533065.001]

[Cites] J Biol Chem. 1999 Nov 5;274(45):31751-4 [10542193.001]

[Cites] J Neurosci. 1999 Nov 15;19(22):9900-12 [10559399.001]

[Cites] J Cell Biol. 2000 Oct 16;151(2):221-34 [11038171.001]

[Cites] J Comp Neurol. 2001 Feb 19;430(4):485-500 [11169482.001]

[Cites] Arch Oral Biol. 2001 Aug;46(8):745-57 [11389866.001]

[Cites] Circ Res. 2002 Mar 22;90(5):506-8 [11909813.001]

[Cites] Hum Mol Genet. 2002 Sep 1;11(18):2113-8 [12189163.001]

[Cites] J Biol Chem. 2003 May 2;278(18):15457-60 [12556455.001]

[Cites] Matrix Biol. 1994 Aug;14(4):275-81 [7827749.001]

[Cites] Mol Biol Cell. 2003 Jul;14(7):2665-76 [12857855.001]

[Cites] Neuron. 2003 Sep 25;40(1):113-27 [14527437.001]

[Cites] DNA Res. 2003 Aug 31;10(4):167-80 [14621295.001]

[Cites] Cell Prolif. 2004 Apr;37(2):161-75 [15030550.001]

[Cites] Annu Rev Biochem. 2004;73:491-537 [15189151.001]

[Cites] Int J Biochem Cell Biol. 2004 Oct;36(10):1861-7 [15203098.001]

[Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]

[Cites] FEBS Lett. 1988 Apr 11;231(1):1-4 [3282918.001]

[Cites] Adv Protein Chem. 1988;39:1-50 [3149870.001]

[Cites] FEBS Lett. 1989 Jul 17;251(1-2):1-7 [2666164.001]

[Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]

[Cites] Genomics. 1996 Feb 15;32(1):54-64 [8786121.001]

[Cites] J Lipid Res. 1996 Feb;37(2):368-81 [9026534.001]

[Cites] Genomics. 1998 Jul 1;51(1):27-34 [9693030.001]

[Cites] Dev Biol. 2005 Feb 15;278(2):381-95 [15680358.001]

[Cites] Mol Psychiatry. 2005 Mar;10(3):251-7 [15583703.001]

[Cites] Glia. 1991;4(1):11-24 [1828781.001]

(PMID = 16981854.001).

[ISSN] 1470-8728

[Journal-full-title] The Biochemical journal

[ISO-abbreviation] Biochem. J.

[Language] eng

[Databank-accession-numbers] RefSeq/ NM/ 172694/ XM/ 3769095

[Grant] United States / NINDS NIH HHS / NS / R01 NS049136

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / MEGF9 protein, human; 0 / MEGF9 protein, mouse; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 62229-50-9 / Epidermal Growth Factor

[Other-IDs] NLM/ PMC1820795